## **Prior Authorization Form**



**Note:** Please provide as much information as possible on this form. Missing data may cause processing delays for requested authorization(s). Attach additional sheets to this form if necessary.

Please fax the completed PA form and any additional informational sheets to Nirvanahealth at the following fax number: +1(866) 871-8565

Patient Information	Prescriber Information	
Patient Name:	Prescriber Name:	
Health Plan Name:	Prescriber Address:	
Patient Insurance Id:	<del></del>	
Patient Date of Birth:	Prescriber Phone: ( )	
Patient Phone:	Prescriber Fax: ( )	
	Prescriber Specialty:	
	Prescriber DEA:	
	Prescriber NPI:	
Medica	tion & Medical Information	
Requested Drug(s) & Strength(s):	[ ] Eucrisa 2 % topical ointment	
Requested Daily Quantity Limit – Amount:		
Requested Daily Quantity Limit – Days:		
Requested Quantity Limit Over Time – Amount:		
Requested Quantity Limit Over Time – Days:		
Requested Quantity Per Rx – Amount:		
Expected Length of Therapy:		
Directions:		
Diagnosis and Diagnosis Codes (ICD-10 Standard Codes):		
List drugs used previously to treat the same condition:		
Additional clinical information or history. Please include any relevant test results and/or medical record notes:		
	Questionnaire	
Q1: I, as the provider or designated representative of the provider, certify and attest that the information provided is complete and accurate and that, upon request, I shall provide any information to RxAdvance that RxAdvance determines is reasonably necessary to verify my responses. (Check only one that apply)		
[] Yes		
[] No		
Q2: Is the member currently treated with this medication? (Check only one that apply)		
[ ] Yes (please list start date of therapy (month/day/year))(*Required)		

## **Prior Authorization Form**



[] No	
Q3: What is the member's diagnosis? (Check only one that apply)	
[] Mild to moderate atopic dermatitis	
[] Other (please specify the member's diagnosis and provide clinical rationale for the second control of the s	ne request)
Q4: Does the member have documentation supporting positive clinical response to ther involvement, reduction in pruritus severity)? (Check only one that apply)	apy (e.g., reduction in body surface area
[] Yes (please provide documentation(s) supporting the positive response of the th(*Required)	erapy)
[ ] No (please provide medical justification for continuation of therapy)(*Required)	
Q5: What is the member's diagnosis? (Check only one that apply)	
[] Mild to moderate atopic dermatitis	
[] Other (please specify the member's diagnosis and provide clinical rationale for the(*Required)	he request)
Q6: Has the member had an inadequate response, intolerance or experienced contraind topical corticosteroid (e.g., triamcinolone acetonide, fluocinolone acetonide)? (Check or	
[] Yes (please specify drug name(s), corresponding contraindication(s) or intolerandate(s) of therapy (month/year))	
[] No	
Q7: Does the affected area is sensitive to use topical corticosteroid (i.e., face, axillae, gr	oin)? (Check only one that apply)
[] Yes	
[ ] No (please provide clinical rationale for the request)(*Required)	
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I Medical Group or its designated representatives may perform a routine audit and request the me accuracy of the information reported on this form.	
Signature of Prescriber or Authorized Representative:	Date:
Print Authorized Representative Name:	